Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 6 points (0.0%) at 14,695 as of Friday, April 26, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 953 issues advancing vs. 1,941 declining with 134 unchanged. The Health Care sector currently sits down 0.38 versus the S&P 500, which is down 0.43. Top gainers within the sector include Celgene Corporation ( CELG), up 1.5%, Teva Pharmaceutical Industries ( TEVA), up 0.7% and Gilead ( GILD), up 0.7%. On the negative front, top decliners within the sector include Covidien ( COV), down 6.58, Agilent Technologies ( A), down 4.40, Vertex Pharmaceuticals ( VRTX), down 1.74, WellPoint ( WLP), down 1.64 and Medtronic ( MDT), down 1.36. TheStreet Ratings group would like to highlight 4 stocks pushing the sector higher today: 4. Watson Pharmaceuticals ( WPI) is one of the companies pushing the Health Care sector higher today. As of noon trading, Watson Pharmaceuticals is up $2.11 (2.13) to $101.00 on heavy volume Thus far, 789,476 shares of Watson Pharmaceuticals exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $99.03-$101.46 after having opened the day at $99.03 as compared to the previous trading day's close of $98.89. Watson Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, marketing, sale, and distribution of generic and brand pharmaceutical products in the United States, western Europe, Canada, Australasia, Asia, South America, and South Africa. Watson Pharmaceuticals has a market cap of $11.0 billion and is part of the drugs industry. The company has a P/E ratio of 13.9, below the S&P 500 P/E ratio of 17.7. Shares are down 1.5% year to date as of the close of trading on Thursday. TheStreet Ratings rates Watson Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, growth in earnings per share, increase in net income, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Watson Pharmaceuticals Ratings Report now. Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.
Watson Pharmaceuticals (NYSE:WPI) is trading at unusually high volume Tuesday with 2.2 million shares changing hands. It is currently at two times its average daily volume and trading up $3.01 (+2.4%).
Watson Pharmaceuticals (NYSE:WPI) hit a new 52-week high Monday as it is currently trading at $127.42, above its previous 52-week high of $126.53 with 1.3 million shares traded as of 9:35 a.m. ET. Average volume has been 1.1 million shares over the past 30 days.
Watson Pharmaceuticals (NYSE:WPI) is trading at unusually high volume Tuesday with 2.8 million shares changing hands. It is currently at 2.7 times its average daily volume and trading up $2.55 (+2.1%).